We provide the latest news
from the world of economics and finance
(RTTNews) - Zevra Therapeutics, Inc. (ZVRA) Monday announced a positive outcome in its placebo-controlled, double-blind Phase 2 clinical trial of KP1077 or serdexmethylphenidate or SDX in patients with idiopathic hypersomnia.
The proof-of-concept study was designed to demonstrate safety and tolerability and was well tolerated at all dose levels evaluated in the trial. The company presented the data in a poster at SLEEP 2024 in Houston, TX.
Adrian Quartel, chief medical officer of Zevra said, "We believe that KP1077 has great potential to provide a differentiated treatment option for patients underserved by currently available therapies."
Idiopathic hypersomnia is a rare sleep disorder characterized by excessive daytime sleepiness.
ZVRA is currently at $4.83, up 3.98 percent from the previous close of $4.65 on a volume of 108,488.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.